Navigation Links
Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms
Date:5/10/2010

y approval both in China and Thailand.

Extending health biotech capacity through south-south collaboration saves Egypt's diabetics

Human insulin has at times been in short supply in Egypt, a considerable health threat to the country's diabetics. To help overcome this, the Holding Company for Biological Products and Vaccines (VACSERA, Giza, Egypt) transferred the technology to produce recombinant insulin from the Chinese company Dongbao (Shanghai, China) and can now produce recombinant insulin locally. As a result, Egypt is capable of meeting its own demands for insulin and ensuring a more affordable product is available to its population in need.

India-Africa Bridge the Technology Divide through joint-ventures

India has transferred technology for diagnosing infectious diseases to South Africa. As part of a joint venture between the publicly funded, LIFElabs in South Africa (Durban, South Africa), and the Indian Tulip Group Diagnostics (Bambolim, India) the Indian company agreed to transfer several diagnostic technologies to South Africa including rapid malaria diagnostic kits, and pregnancy diagnostic kits. The Tulip Group committed to transfer the technology and provide substantial capacity and technical assistance. By transferring the technology to South Africa, the South African firms are able to diagnose diseases locally and rapidly.


'/>"/>

Contact: Terry Collins
terrycollins@rogers.com
416-538-8712
McLaughlin-Rotman Centre for Global Health
Source:Eurekalert

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Hybrid computer materials may lead to faster, cheaper technology
2. Cheaper materials could be key to low-cost solar cells
3. Stanford researchers find a quicker, cheaper way to sort isotopes
4. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
5. Amazing Treatment Relieves Serious Back Pain Without Dangerous Drugs, Injections or Surgery!
6. New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents
7. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
8. Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016
9. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
10. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
11. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Mar. 04, 2015 Research and Markets ... of the "Global Biologics and Biosimilars Industry ... , The Global Biologics and Biosimilars ... study on the current state of the biologics ... a basic overview of the industry including definitions, ...
(Date:3/4/2015)... , March 4, 2015 AcelRx ... specialty pharmaceutical company focused on the development and ... acute and breakthrough pain, today announced that it ... results after market close on Monday, March 9th, ... call at 4:30 p.m. Eastern Time (1:30 p.m. ...
(Date:3/4/2015)... , March 4, 2015 ... Paris in December 2011, ,SARAH, ... yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma ... late 2016.   SARAH, a large French ... (hepatocellular carcinoma, or HCC) has completed patient enrolment, exceeding ...
(Date:3/3/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be ... Miami, FL on March 10, 2015 at ... Chief Financial Officer, will provide a corporate overview. ... Halozyme,s corporate website at www.halozyme.com , and a recording ... To access the live webcast, please log on to Halozyme,s ...
Breaking Biology Technology:Global Biologics and Biosimilars Industry Report 2015-2020 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2
... Energy is the biggest challenge in the world, and we ... of energy inefficiencies can be attributed to transportation (27 percent), ... calculated by the U.S. Energy Information Administration statistics ... G.P. Yeh of Fermi Labs . He also said ...
... Madison, Wis. - As the completion of an audit ... has abandoned another costly IT project. , ,According to a ... Department of Workforce Development has decided to stop ... track unemployment claims. The system, known as Enhanced Automated Benefits ...
... fellow travelers a thing or two about commuting. , ,The ... an executive-in-residence and one of its portfolio companies, Caden ... , Gregg Fergus And since Fergus has been ... his new posts reduce the distance between home and work. ...
Cached Biology Technology:Energy conservation might take us farther than renewable fuels 2Energy conservation might take us farther than renewable fuels 3Energy conservation might take us farther than renewable fuels 4Energy conservation might take us farther than renewable fuels 5Energy conservation might take us farther than renewable fuels 6State of Wisconsin dumps another tech project 2Biotech executive books a career flight that's closer to home 2Biotech executive books a career flight that's closer to home 3
(Date:2/18/2015)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. , Cowen and Company Health ... 3, 2015 at 11.20 a.m. Eastern Time , Raymond ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... in the November 2008 issue of BioScience ... an Era of Genomics and Proteomics. David Emerson, Liane ... genomics and proteomics are changing techniques used for identifying ... levels of discrimination, but standards for their use must ...
... known that it,s possible for one gene to produce slightly ... certain sequences from the messenger RNA. Now, an MIT team ... both far more prevalent and varies more between tissues than ... 94 percent, generate more than one form of their protein ...
... to immune system cells called T-lymphocytes that target a ... fight a form of childhood cancer called neuroblastoma, said ... Hospital in a report that appears online today in ... a way to convert a naturally occurring problem into ...
Cached Biology News:BioScience tip sheet, November 2008 2Human genes sing different tunes in different tissues 2A double-barreled immune cell approach for neuroblastoma 2
... platform for fully automated systems for a ... be configured for applications ranging from compound ... closed loop screening, which means it has ... cherry picking and follow up studies all ...
... Building on over 20 years of experience ... the Life Sciences, the Freedom EVO platform ... expansion according to future needs. Together with ... system is equipped to successfully operate genomics, ...
... Systems provide fast and reliable automation ... and drug development laboratories. Staccato Custom ... specifications, providing solutions that are tailored ... Custom Systems are controlled with either ...
... medium binding) polystyrene surface is hydrophobic ... passive interactions,• Is suitable primarily for ... as antibodies, that have large hydrophobic ... surface,• Binding capacity of approximately 250 ...
Biology Products: